The impact of direct oral anticoagulants on viscoelastic testing - A systematic review

Sebastian D Sahli; Clara Castellucci; Tadzio R Roche; Julian Rössler; Donat R Spahn; Alexander Kaserer

doi:10.3389/fcvm.2022.991675

The impact of direct oral anticoagulants on viscoelastic testing - A systematic review

Front Cardiovasc Med. 2022 Nov 7:9:991675. doi: 10.3389/fcvm.2022.991675. eCollection 2022.

Authors

Sebastian D Sahli¹, Clara Castellucci¹, Tadzio R Roche¹, Julian Rössler², Donat R Spahn¹, Alexander Kaserer¹

Affiliations

¹ Institute of Anesthesiology, University and University Hospital Zurich, Zurich, Switzerland.
² Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, United States.

Abstract

Background: In case of bleeding patients and in acute care, the assessment of residual direct oral anticoagulant (DOAC) activity is essential for evaluating the potential impact on hemostasis, especially when a timely decision on urgent surgery or intervention is required. Viscoelastic tests are crucial in a modern goal-directed coagulation management to assess patients' coagulation status. However, the role of viscoelastic test to detect and quantify residual DOAC plasma levels is controversially discussed. The aim of this review was to systematically summarize the evidence of viscoelastic tests for the assessment of residual DOAC activity.

Method: PubMed, Embase, Scopus, and the Cochrane Library were searched for original articles investigating the effect of rivaroxaban, apixaban, edoxaban, or dabigatran plasma levels on different viscoelastic tests of the adult population from database inception to December 31, 2021.

Results: We included 53 studies from which 31 assessed rivaroxaban, 22 apixaban, six edoxaban, and 29 dabigatran. The performance of viscoelastic tests varied across DOACs and assays. DOAC specific assays are more sensitive than unspecific assays. The plasma concentration of rivaroxaban and dabigatran correlates strongly with the ROTEM EXTEM, ClotPro RVV-test or ECA-test clotting time (CT) and TEG 6s anti-factor Xa (AFXa) or direct thrombin inhibitor (DTI) channel reaction time (R). Results of clotting time (CT) and reaction time (R) within the normal range do not reliable exclude relevant residual DOAC plasma levels limiting the clinical utility of viscoelastic assays in this context.

Conclusion: Viscoelastic test assays can provide fast and essential point-of-care information regarding DOAC activity, especially DOAC specific assays. The identification and quantification of residual DOAC plasma concentration with DOAC unspecific viscoelastic assays are not sensitive enough, compared to recommended anti-Xa activity laboratory measurements.

Systematic review registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=320629], identifier [CRD42022320629].

Keywords: ClotPro; DOAC; FII inhibitor; FXa inhibitor; ROTEM; TEG; point-of-care.

Publication types

Systematic Review